Last reviewed · How we verify
Melarsamin (melarsomine)
At a glance
| Generic name | melarsomine |
|---|---|
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site reactions (overall)
- Coughing/Gagging
- Depression/Lethargy
- Anorexia/Inappetence
- Fever
- Lung congestion
- Vomiting
- Hypersalivation
- Panting
- Injection site swelling/edema/seroma
- Injection site pain/discomfort/irritation
- Injection site myalgia with tenderness
Serious adverse events
- Severe injection site reactions
- Posttreatment death
- Abdominal hemorrhage
- DIC (Disseminated Intravascular Coagulation)
- Pneumonia
- Pancreatitis
- Convulsion/Seizure
- Colitis
- Anemia
- Hemoglobinemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melarsamin CI brief — competitive landscape report
- Melarsamin updates RSS · CI watch RSS
- portfolio CI